Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03156023 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03156023 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 34 participants.
The verdict
NCT03156023, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
A study to evaluate safety and tolerability and characterize the pharmacokinetic (PK) profile of rozibafusp alfa following multiple dose administration in adults with rheumatoid arthritis (RA).
Interventions
- DRUG Placebo
- DRUG Rozibafusp Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2020-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03156023
The ClinicalTrials.gov registry entry for NCT03156023 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03156023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03156023 about?
NCT03156023 is a clinical study titled "Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis". A study to evaluate safety and tolerability and characterize the pharmacokinetic (PK) profile of rozibafusp alfa following multiple dose administration in adults with rheumatoid arthritis (RA).
What is the current status of trial NCT03156023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-08-14. Estimated completion is 2020-06-12.
What interventions are being tested in trial NCT03156023?
The interventions under investigation include: Placebo (DRUG), Rozibafusp Alfa (DRUG).
Who is sponsoring clinical trial NCT03156023?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.